Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 in Idiopathic CD4 Lymphocytopenia
NCT00839436Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2009
- Primary completion
- May 2014
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of recombinant human interleukin-7 in Idiopathic CD4 lymphocytopenia (ICL) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Adverse Events and Toxicities Associated With CYT107 at 48 weeks. Started Feb 2009; status: terminated.
02
Drugs
recombinant human interleukin-7
03
Conditions
Idiopathic CD4 lymphocytopenia (ICL)
Beyond the preview
Go deeper on NCT00839436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00839436.